Targeting cell cycle regulators in hematologic malignancies

被引:96
作者
Aleem, Eiman [1 ,2 ]
Arceci, Robert J. [1 ]
机构
[1] Univ Arizona, Coll Med Phoenix, Ronald A Matricaria Inst Mol Med, Phoenix Childrens Hosp,Dept Child Hlth, Phoenix, AZ USA
[2] Alexandria Univ, Fac Sci, Dept Zool, Alexandria, Egypt
关键词
Cdk6; Cdk1; Wee-1; Cyclin C; Cdk8; Cdk19; leukemia; mouse models;
D O I
10.3389/fcell.2015.00016
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hematologic malignancies represent the fourth most frequently diagnosed cancer in economically developed countries. In hematologic malignancies normal hematopoiesis is interrupted by uncontrolled growth of a genetically altered stem or progenitor cell (HSPC) that maintains its ability of self-renewal. Cyclin-dependent kinases (CDKs) not only regulate the mammalian cell cycle, but also influence other vital cellular processes, such as stem cell renewal, differentiation, transcription, epigenetic regulation, apoptosis, and DNA repair. Chromosomal translocations, amplification, overexpression and altered CDK activities have been described in different types of human cancer, which have made them attractive targets for pharmacological inhibition. Mouse models deficient for one or more CDKs have significantly contributed to our current understanding of the physiological functions of CDKs, as well as their roles in human cancer. The present review focuses on selected cell cycle kinases with recent emerging key functions in hematopoiesis and in hematopoietic malignancies, such as CDK6 and its role in MLL-rearranged leukemia and acute lymphocytic leukemia, CDK1 and its regulator WEE-1 in acute myeloid leukemia (AML), and cyclin C/CDK8/CDK19 complexes in T-cell acute lymphocytic leukemia. The knowledge gained from gene knockout experiments in mice of these kinases is also summarized. An overview of compounds targeting these kinases, which are currently in clinical development in various solid tumors and hematopoietic malignances, is presented. These include the CDK4/CDK6 inhibitors (palbociclib, LEE011, LY2835219), pan-CDK inhibitors that target CDK1 (dinaciclib, flavopiridol, AT7519, TG02, P276-00, terampeprocol and RGB 286638) as well as the WEE-1 kinase inhibitor, MK-1775. The advantage of combination therapy of cell cycle inhibitors with conventional chemotherapeutic agents used in the treatment of AML, such as cytarabine, is discussed.
引用
收藏
页数:22
相关论文
共 291 条
[1]   Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1 [J].
Aarts, Marieke ;
Sharpe, Rachel ;
Garcia-Murillas, Isaac ;
Gevensleben, Heidrun ;
Hurd, Melissa S. ;
Shumway, Stuart D. ;
Toniatti, Carlo ;
Ashworth, Alan ;
Turner, Nicholas C. .
CANCER DISCOVERY, 2012, 2 (06) :524-539
[2]   Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia [J].
Agirre, Xabier ;
Vilas-Zornoza, Amaia ;
Jimenez-Velasco, Antonio ;
Ignacio Martin-Subero, Jose ;
Cordeu, Lucia ;
Garate, Leire ;
San Jose-Eneriz, Edurne ;
Abizanda, Gloria ;
Rodriguez-Otero, Paula ;
Fortes, Puri ;
Rifon, Jose ;
Bandres, Eva ;
Jose Calasanz, Maria ;
Martin, Vanesa ;
Heiniger, Anabel ;
Torres, Antonio ;
Siebert, Reiner ;
Roman-Gomez, Jose ;
Prosper, Felipe .
CANCER RESEARCH, 2009, 69 (10) :4443-4453
[3]   TFIIH is negatively regulated by cdk8-containing mediator complexes [J].
Akoulitchev, S ;
Chuikov, S ;
Reinberg, D .
NATURE, 2000, 407 (6800) :102-106
[4]   Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways [J].
Alarcon, Claudio ;
Zaromytidou, Alexia-Ileana ;
Xi, Qiaoran ;
Gao, Sheng ;
Yu, Jianzhong ;
Fujisawa, Sho ;
Barlas, Afsar ;
Miller, Alexandria N. ;
Manova-Todorova, Katia ;
Macias, Maria J. ;
Sapkota, Gopal ;
Pan, Duojia ;
Massague, Joan .
CELL, 2009, 139 (04) :757-769
[5]   Cdc2-cyclin E complexes regulate the G1/S phase transition [J].
Aleem, E ;
Kiyokawa, H ;
Kaldis, P .
NATURE CELL BIOLOGY, 2005, 7 (08) :831-U93
[6]  
Aleem Eiman, 2006, V42, P271, DOI 10.1007/023
[7]   Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling with differentiation during neurogenesis [J].
Ali, Fahad ;
Hindley, Chris ;
McDowell, Gary ;
Deibler, Richard ;
Jones, Alison ;
Kirschner, Marc ;
Guillemot, Francois ;
Philpott, Anna .
DEVELOPMENT, 2011, 138 (19) :4267-4277
[8]   Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation [J].
Alt, JR ;
Cleveland, JL ;
Hannink, M ;
Diehl, JA .
GENES & DEVELOPMENT, 2000, 14 (24) :3102-3114
[9]   Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor [J].
Alvarez-Fernandez, Stela ;
Jesus Ortiz-Ruiz, Maria ;
Parrott, Tracy ;
Zaknoen, Sara ;
Ocio, Enrique M. ;
San Miguel, Jesus ;
Burrows, Francis J. ;
Esparis-Ogando, Azucena ;
Pandiella, Atanasio .
CLINICAL CANCER RESEARCH, 2013, 19 (10) :2677-2687
[10]   CDK6, a new target in MLL-driven leukemia [J].
Antony-Debre, Ileana ;
Steidl, Ulrich .
BLOOD, 2014, 124 (01) :5-6